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Abstract
Maternal smoking during pregnancy is one proposed risk factor for gastroschisis, but reported 
associations have been modest, suggesting that differences in genetic susceptibility might play a 
role. We included 108 non-Hispanic white and 62 Hispanic families who had infants with 
gastroschisis, and 1147 non-Hispanic white and 337 Hispanic families who had liveborn infants 
with no major structural birth defects (controls) in these analyses. DNA was extracted from buccal 
cells collected from infants and mothers, and information on periconceptional smoking history 
was obtained from maternal interviews, as part of the National Birth Defects Prevention Study. 
We analyzed five polymorphisms in three genes that code for enzymes involved in metabolism of 
some cigarette smoke constituents (CYP1A1, CYP1A2, and NAT2). Logistic regression models 
were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) independently for 
maternal smoking and maternal and infant gene variants, and to assess joint associations of 
maternal smoking and maternal or infant gene variants with gastroschisis. In analyses adjusted for 
maternal age at delivery and stratified by maternal race-ethnicity, we identified three suggestive 
associations among 30 potential associations with sufficient numbers to calculate ORs: 
CYP1A1*2A for non-Hispanic white mothers who smoked periconceptionally (aOR=0.38, 95% CI 
0.15-0.98), and NAT2*6 for Hispanic non-smoking mothers (aOR=2.17, 95% CI 1.12-4.19) and 
their infants (aOR=2.11, 95% CI 1.00-4.48). This analysis does not support the occurrence of 
effect modification between periconceptional maternal smoking and most of the xenobiotic 
metabolizing enzyme gene variants assessed.
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INTRODUCTION
Gastroschisis is a herniation of the intestines through a defect of the abdominal wall lateral 
to the umbilicus (usually on the right side), and it is not covered by a membrane [Ledbetter, 
2012]. This congenital anomaly affects approximately 4.5 infants per 10,000 U.S. live births 
[Parker et al., 2010]. Many epidemiological studies have found a positive, albeit modest, 
association between maternal smoking during pregnancy and gastroschisis [Chabra et al., 
2011; Hackshaw et al., 2011; Paranjothy et al., 2012]. Associations could be larger for 
specific individuals given the potential for genetic differences in maternal or fetal 
metabolism of chemicals in cigarette smoke.
The metabolism of chemicals in smoke occurs in two phases catalyzed by xenobiotic-
metabolizing enzymes (XMEs). CYP1A1*2A (rs4646903) and CYP1A2*1F (rs762551) are 
functional single nucleotide polymorphisms (SNPs) reported to increase inducibility of 
cytochrome P-450 (CYP) activity during phase I [Georgiadis et al., 2005; Human CYP 
Allele Nomenclature Committee Database], and CYP1A2*1C (rs2069514) is a functional 
SNP reported to decrease inducibility of CYP activity [Human CYP Allele Nomenclature 
Committee Database]. Elevated CYP activity can increase the toxicity of cigarette smoke 
constituents that are metabolically activated to reactive intermediates by the induced 
enzymes [Guengerich and Shimada, 1991], although the level of susceptibility might vary 
dependent upon the activity of other phase I as well as phase II enzymes. NAT2*5 
(rs1801280) and NAT2*6 (rs1799930) are functional variants reported to decrease N-
acetyltransferase (NAT) activity during phase II [Consensus Human NAT Gene 
Nomenclature Database], resulting in prolonged exposure to toxic intermediates produced 
by phase I reactions [Boukouvala and Fakis, 2005].
Other studies have reported joint associations of these and other XME gene variants and 
exposure to cigarette smoke with risk for birth defects other than gastroschisis [Chevrier et 
al., 2008; Hecht et al., 2007; Lammer et al., 2004; Sommer et al., 2011] as well as joint 
associations of other gene variants involved in vascular disruption and exposure to cigarette 
smoke with risk for gastroschisis [Lammer et al., 2008; Torfs et al., 2006]. We analyzed five 
SNPs in three XME genes (CYP1A1, CYP1A2, and NAT2) in mothers and infants to assess 
their potential association with gastroschisis, and to assess the effect of their possible 
interaction with maternal smoking.
MATERIALS AND METHODS
Study Population
We used data from the National Birth Defects Prevention Study (NBDPS), a multisite, 
population-based, case-control study of major birth defects that included a maternal 
interview and self-collection of buccal (cheek) cells from each case and control infant and 
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his/her mother and father. Detailed methodology for the NBDPS has been published 
previously [Rasmussen et al., 2002; Yoon et al., 2001]. Briefly, case infants with selected 
major birth defects were identified using birth defects surveillance systems at the 10 
participating sites. Liveborn control infants without major birth defects were randomly 
selected from birth certificates or birth hospital data from the same region and time period. 
Clinical geneticists reviewed data abstracted from medical records using standardized case 
definitions. Case infants with known chromosomal abnormalities or single gene disorders 
were excluded. Standardized computer assisted telephone interviews were conducted in 
English or Spanish between six weeks and 24 months after the estimated date of delivery 
(EDD). Women were asked about their exposures from three months before conception until 
delivery. Following completion of the interview, buccal cell collection kits that included 
cytobrushes for the mother, her child, and the child’s father (two brushes per participant) 
were mailed. Buccal cell collection initiation varied by site, and samples were requested 
only from mothers whose interviews were completed after collection began. Institutional 
Review Boards (IRBs) at the Centers for Disease Control and Prevention (CDC) and each 
study site have approved the NBDPS.
These analyses included infants of non-Hispanic white or Hispanic mothers with an EDD 
between October 1, 1997 and December 31, 2003. Race-ethnicity was self-reported by each 
mother, and infants were analyzed according to their mother’s race-ethnicity. Infants of 
mothers of other race-ethnicities were not included because of small numbers of case infants 
(i.e., < 4) with mothers who reported periconceptional smoking and with analyzable buccal 
cell samples. Samples from mothers were removed from analyses if she reported using an 
egg or embryo donor. DNA samples from the infant, mother, or both were analyzed; father 
samples were not included in these analyses. Case infants had gastroschisis with or without 
other major congenital anomalies, and samples were available only if they were liveborn. 
Infants diagnosed with limb body wall defects were excluded from these analyses.
Smoking History
Infants and mothers were classified as exposed to periconceptional maternal smoking if the 
mother reported any smoking at any time in the month before or in the first three months of 
pregnancy, since gastroschisis occurs during the third and fourth weeks post-fertilization 
[Sadler and Feldkamp, 2008]. Infants and mothers were classified as unexposed if the 
mother did not report any smoking in the month before and in the first three months of 
pregnancy.
DNA Extraction
Laboratories at each participating site extracted DNA from buccal cells using a variety of 
methods for samples collected prior to mid-2003 [Rasmussen et al., 2002]. A laboratory 
atCDC extracted DNA from Georgia participant samples and from all sites after mid-2003 
using a modified phenol-chloroform method [Garcia-Closas et al., 2001]. Human genomic 
DNA (gDNA) yields were assessed by quantitative real-time PCR using TaqMan® 
Ribonuclease P assays (Applied Biosystems, Foster City, CA). Specimens with DNA 
concentrations less than 0.1ng/μl were excluded. DNA quality and family relationships were 
assessed using tetranucleotide short tandem repeats (STRs) as described previously 
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[Gallagher et al., 2011]. DNA samples from inconsistent mother-infant pairs were excluded; 
consistent pairs and unpaired mothers and infants were included. Positive and negative 
controls were included in each DNA extraction and quantitation assay.
Genotyping Methods
We analyzed five SNPs in three genes (CYP1A1, CYP1A2, and NAT2) that were selected 
based on their effect on XME activity [Consensus Human NAT Gene Nomenclature 
Database; Human CYP Allele Nomenclature Committee Database], their minor allele 
frequencies [Packer et al., 2006], and assay success in preliminary validation studies. 
Appendix 1 provides more information on the selected XME gene variants. Genotyping was 
completed on either gDNA or whole genome amplified (WGA) products from mothers and 
infants using Pyrosequencing® technology (Qiagen, Valencia, CA). Methods and quality 
assessment results were described previously [Gallagher et al., 2011]. Replica genotyping 
was performed on separate days for at least 4% of specimens from each genotyping plate. 
For each mother-infant pair, SNPs that were inconsistent with Mendelian inheritance were 
removed from further analyses. Specimens with missing data for one or more SNPs were 
removed from further analyses. The laboratory at CDC successfully completed external 
quality assessment (protocols are available upon request).
Statistical Analyses
Data from control mothers were assessed for Hardy-Weinberg equilibrium by race-ethnicity 
for each of the five SNPs studied using Chi square tests. Mendelian errors were identified 
and allele frequencies were calculated using PedCheck Version 1.00 [O’Connell and Weeks, 
1998] and PLINK Version 1.07 [Purcell et al., 2007]. Maternal age at delivery, alcohol use, 
body mass index, obesity, parity, and education were assessed as potential confounders 
using Chi square tests in non-Hispanic white and Hispanic control mothers separately. 
Maternal age at delivery was also assessed as a potential effect modifier by completing 
stratified analyses (< 25 years vs ≥ 25 years). Maternal age at delivery (continuous) was 
included in the logistic regression models.
Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence 
intervals (CIs) using PASW Statistics 18, Release Version 18.0.0 (SPSS, Inc., 2009, 
Chicago, IL, www.spss.com). Maternal age-adjusted associations between smoking and 
gastroschisis were assessed, stratified by race-ethnicity. Maternal age-adjusted associations 
between maternal or infant XME gene variants and gastroschisis with and without 
stratification by maternal periconceptional smoking status were assessed separately in non-
Hispanic white and Hispanic mothers and infants using dominant or recessive inheritance 
models. For all analyses, dominant inheritance models were used when assessing 
CYP1A1*2A, CYP1A2*1C, NAT2*5, and NAT2*6 (i.e., persons who had one or two copies 
of the variant allele were combined and compared to persons who had zero copies) because 
small numbers of mothers and infants carrying two copies of the variant allele limited 
analyses of other inheritance models. Recessive inheritance models were used when 
assessing CYP1A2*1F (i.e., persons who had two copies of the variant allele were compared 
to persons who had zero or one copy of the variant allele combined) because small numbers 
of mothers and infants carrying two copies of the wild-type allele limited analyses of other 
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inheritance models. After stratification, analyses were completed only if there were four or 
more mothers or infants in each genotype category.
To assess the contribution of having any high risk XME gene variants in the mother and her 
infant, we also dichotomized combined gene variants from available mother-infant pairs (0 
(referent group) or ≥1) for each of the five XME gene variants. These analyses were 
completed only when DNA was available from both a mother and her infant. If a mother or 
her infant carried two copies of CYP1A2*1F, the pair was categorized as having a high risk 
gene variant; for all other variant alleles (i.e., CYP1A1*2A, CYP1A2*1C, NAT2*5, and 
NAT2*6), if a mother or her infant carried one or two copies of the variant allele, the pair 
was categorized as having a high risk gene variant.
RESULTS
Interview and Buccal Cell Collection Participation Rates
The interview participation rate was 72% for all mothers of infants with gastroschisis 
(n=504), and 69% for all mothers of control infants (n=4949). Buccal cell samples were 
requested from 455 case families and 4251 control families and were submitted for the 
mother, infant, or both for 47% of families with gastroschisis (n=215), and 43% of control 
families (n=1834). After excluding families with reported maternal race-ethnicity other than 
non-Hispanic white or Hispanic, and specimens that did not pass quality control (i.e., STR 
or SNP results were inconsistent with Mendelian inheritance; DNA quantity was <0.1 ng/μl; 
data were missing for >1 SNP), samples from 108 non-Hispanic white case families (76 
mother-infant pairs; 29 mother only; and 3 infant only), 62 Hispanic case families (36 
mother-infant pairs; 22 mother only; and 4 infant only), 1147 non-Hispanic white control 
families (890 mother-infant pairs; 210 mother only; and 47 infant only), and 337 Hispanic 
control families (233 mother-infant pairs; 72 mother only; and 32 infant only) were included 
(Figure 1).
Study Participant Characteristics
There were some differences in selected maternal demographic and behavioral risk factors 
for gastroschisis among case and control infants (Table I). Mothers of infants with 
gastroschisis were younger, less educated, and more likely to be underweight.
Quality Control
Genotype call rates were between 99 and 100 percent for all five variants. The genotype 
distribution of each variant did not deviate from Hardy-Weinberg equilibrium (P>0.05) in 
non-Hispanic white or Hispanic mothers of control infants. The minor allele frequencies of 
each genetic variant in non-Hispanic white and Hispanic control mothers are listed in 
Appendix 1 and were consistent with reported published frequencies [Chang et al., 2009; 
Sherry et al., 2001; Swinney et al., 2011].
Association of Maternal Smoking and Gastroschisis
Of the potential confounders assessed, only maternal age at delivery (continuous) and 
maternal education (≤12 years or >12 years) were found to be associated with the XME gene 
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variants (Appendix 2). Because maternal age and maternal education are correlated and 
young maternal age at delivery is an established risk factor for gastroschisis [Rasmussen and 
Frias, 2008], we included only maternal age at delivery in the models. Among non-Hispanic 
white and Hispanic control mothers included in these genetic analyses, 20.1% and 9.8%, 
respectively, reported smoking in the month before pregnancy or during the first trimester. 
Nearly identical, elevated maternal age-adjusted ORs were observed for gastroschisis risk 
and exposure to maternal periconceptional smoking in both racial-ethnic groups; however, 
the finding was statistically significant only in non-Hispanic white mothers (aOR=2.07, 95% 
CI 1.33-3.23, P<0.01) (Table II).
Association of Maternal and Infant XME Gene Variants with Gastroschisis Risk
A suggestive maternal-age adjusted association of NAT2*6 with gastroschisis was observed 
in Hispanic mothers (aOR=1.88, 95% CI 1.04-3.39, P=0.04) and their infants (aOR=1.93, 
95% CI 0.96-3.88, P=0.07) (Table III). An age-adjusted association of NAT2*6 with 
gastroschisis was not observed in non-Hispanic white mothers or their infants and adjusted 
associations of CYP1A1*2A, CYP1A2*1C, CYP1A2*1F, and NAT2*5 with gastroschisis 
were not observed in mothers of either race-ethnicity or their infants (Table III). Similar 
results were observed in analyses stratified by maternal age at delivery (data not shown).
Modifying Effects of XME Gene Variants on the Association of Maternal Smoking and 
Gastroschisis
After stratifying by smoking status, a suggestive maternal age-adjusted association of 
NAT2*6 with gastroschisis continued to be observed in Hispanic non-smoking mothers 
(aOR=2.17, 95% CI 1.12-4.19, P=0.02) and their infants (aOR=2.11, 95% CI 1.00-4.48, 
P=0.05); no association was observed in Hispanic smoking mothers (Table IV). No 
statistically significant age-adjusted associations of NAT2*6 with gastroschisis were 
observed in non-Hispanic white smoking or non-smoking mothers or their infants (Table 
IV). A suggestive maternal age-adjusted association of CYP1A1*2A with gastroschisis was 
observed in non-Hispanic white smoking mothers (aOR=0.38, 95% CI 0.15-0.98, P=0.05) 
that was not observed in their infants or in non-Hispanic white non-smoking mothers or their 
infants (Table IV). No associations of CYP1A1*2A with gastroschisis were observed in 
Hispanic non-smoking mothers or their infants (Table IV). No statistically significant age-
adjusted associations were observed between CYP1A2*1C, CYP1A2*1F or NAT2*5 and 
gastroschisis (Table IV).
A suggestive maternal age-adjusted association of NAT2*6 with gastroschisis was observed 
in non-Hispanic white (aOR=3.41, 95% CI 1.25-9.31, P=0.02) and Hispanic (aOR=3.31, 
95% CI 1.42-7.75, P=0.01) non-smoking mother-infant pairs when comparing those pairs 
carrying one or more high risk gene variant to those pairs with no high risk gene variant 
(Table V). A statistically significant adjusted association of NAT2*6 with gastroschisis was 
not observed in non-Hispanic white smoking mother-infant pairs (Table V). No statistically 
significant associations were observed in non-smoking mother-infant pairs of either race-
ethnicity for the other four gene variants and were not observed in non-Hispanic white 
smoking mother-infant pairs for three of the four gene variants with sufficient numbers 
(Table V).
Jenkins et al. Page 6














Our data support a statistically significant positive association between maternal 
periconceptional smoking and gastroschisis among non-Hispanic white mothers, and suggest 
that maternal CYP1A1*2A variants might mitigate the toxic effects of some cigarette smoke 
constituents for gastroschisis risk in infants of non-Hispanic white mothers. However, most 
of the selected XME gene variants do not act as effect modifiers for maternal smoking and 
gastroschisis in these data. Suggestive associations of NAT2*6 in Hispanic non-smoking 
mothers and their infants were also observed. No effects were observed for CYP1A2*1C, 
CYP1A2*1F or NAT2*5.
In a broader set of NBDPS data (not limited by race or participation in the genetic portion of 
the study), risk factors and maternal demographics for gastroschisis cases and controls were 
similar [Werler et al., 2009].
Twenty percent of non-Hispanic white and almost ten percent of Hispanic mothers of 
control infants reported periconceptional smoking. These percentages are similar to those for 
all reproductive-aged women using data from the 2006 Behavioral Risk Factor Surveillance 
System [CDC, 2008].
Our main results on maternal smoking and gastroschisis agree with a comprehensive review 
of 12 studies of maternal smoking that showed a clear, albeit modest, association with 
gastroschisis (OR=1.50, 95% CI 1.28-1.76) [Hackshaw et al., 2011].
XME Gene Variants and Gastroschisis Risk
The elevated effect estimates observed for gastroschisis risk in Hispanic mothers and their 
infants who carried one or two copies of NAT2*6 (Table III) are biologically plausible 
because the resulting decrease in NAT2 activity [Consensus Human NAT Gene 
Nomenclature Database] leads to increased susceptibility to the toxic effects of the 
intermediates formed in phase I reactions. NAT2*6 has not been reported in previous studies 
to be associated with gastroschisis.
XME Gene Variant – Maternal Smoking Exposure Interactions and Gastroschisis
Analyses of CYP variants were stratified by maternal periconceptional smoking status 
because CYP1A1 and CYP1A2 are induced by exposure to cigarette smoke [Gunes and 
Dahl, 2008]. We expected individuals carrying CYP1A1*2A to be more susceptible to the 
toxic effects of chemicals in cigarette smoke because this variant has been reported to 
increase enzyme activity [Georgiadis et al., 2005] and lead to increased toxic intermediates; 
however, mothers carrying this variant who smoked periconceptionally appeared to be less 
likely to have an infant with gastroschisis (Table IV). The CYP1A1*2A fetal variant has 
been reported to play a protective role for oral cleft risk in children whose mothers were 
exposed to secondhand tobacco smoke during the first trimester [Chevrier et al., 2008]. 
Kurahashi and colleagues [Kurahashi et al., 2005] reported a protective effect of the 
maternal variant for hypospadias risk in the offspring of Japanese mothers (smoking and 
non-smoking); however, there was no interaction effect. In our study, this was the only 
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variant that had a suggestive modifying effect on maternal periconceptional smoking. 
CYP1A1*2A has not been reported in previous studies to be associated with gastroschisis.
It is unclear whether gastroschisis risk is influenced more by maternal or fetal genes or both 
equally. We observed suggestive adjusted associations between NAT2*6 and gastroschisis 
for Hispanic and non-Hispanic white non-smoking mother-infant pairs. The suggestive 
associations that were consistently observed in our analyses between NAT2*6 and 
gastroschisis in Hispanic families have not been reported previously. Although the variant 
has not been previously reported to be associated with gastroschisis, it has been associated 
with cleft lip with or without cleft palate [Lie et al., 2008], including reports of having a 
modifying effect on the association between maternal smoking and orofacial clefts [Shi et 
al., 2007].
In our study, CYP1A1*2A was the only variant that acted as an effect modifier for maternal 
periconceptional smoking and gastroschisis. The effects we observed in mothers and infants 
who were not exposed to periconceptional smoking could be due to interactions of NAT2*6 
with other exposures. Our data were analyzed separately for each race-ethnicity because of 
large differences in allele frequencies, which limited our ability to assess interactions. 
Further sub-classification of the Hispanic population was not completed, and genetic 
admixture within this population might have an impact on our results [Martinez, 1998]. 
Maternal and infant genotypes were not adjusted for each other when analyses were 
completed separately which could be a potential source of confounding. Other limitations 
included the use of self-reported maternal race-ethnicity, which was used to classify the 
infant race-ethnicity, and the use of self-reported smoking that did not include data on level 
of smoking or secondhand smoking exposures. These exploratory analyses were completed 
with limited numbers of families and by reporting results without correcting for multiple 
testing we can provide more liberal data that can better inform future studies.
Strengths of our study included the assessment of data from a large population-based, case-
control study of risk factors for birth defects with both genetic and environmental exposure 
data and standardized case definitions.
This study focused on a small number of XME genes because of limited DNA quantity and 
stringent quality control. Other gene variants in the XME pathway might affect gastroschisis 
risk through their effect on smoking behavior (e.g. CYP2A6 [Tyndale and Sellers, 2002]) or 
important detoxification reactions (e.g., glutathione S-transferase [Garlantezec et al., 2012]). 
Other exposures might also explain, in part, the contradictory associations with maternal 
smoking observed in our study. CYP1A1 and CYP1A2 are inducible by a large number of 
common exposures in addition to cigarette smoke, such as cruciferous vegetables [Vistisen 
et al., 1992], caffeine [Tantcheva-Poor et al., 1999], and charcoal-grilled food [Kall and 
Clausen, 1995]. Oral contraceptives [Abernethy and Todd, 1985] and apiaceous vegetables 
[Peterson et al., 2006] inhibit enzyme activity. NAT2 metabolizes a wide range of drugs, 
including isoniazid (antituberculotic), hydralazine (antihypertensive), sulfonamides 
(antibacterials), and caffeine [Daly, 2003; Kawamura et al., 2005].
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We believe this is the first report of CYP1A1*2A as a possible protective variant against 
gastroschisis in the offspring of women who smoke during the periconceptional period and 
also the first report of a suggestive association between NAT2*6 and gastroschisis risk for 
Hispanic non-smoking mothers and their infants. Although the sample size is small, to our 
knowledge, this is the largest case-control study examining genetic and non-genetic risk 
factors for gastroschisis that has been completed to date. Five previous studies of genetic 
risk factors for gastroschisis included no more than 57 case families (whereas we included 
170 case families) [Cardonick et al., 2005; Feldkamp et al., 2012; Komuro et al., 2001; 
Lammer et al., 2008; Torfs et al., 2006]. It is challenging to conduct genetic epidemiologic 
analyses on such a rare birth defect, especially one that disproportionally affects younger 
mothers who typically have lower participation in biospecimen collection. We feel the value 
of these exploratory analyses is to inform studies that can build upon these methodologies, 
resources and results. Future studies are needed to confirm our findings with these gene 
variants and to investigate other exposures or other XME genes and exposure to 
periconceptional smoking.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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